Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of Lipustobart (LZM009) in Advanced Solid Tumors
NCT03286296Phase 1Completed
- Sponsor
- Livzon Pharmaceutical Group Inc.
- Start
- Aug 2017
- Primary completion
- Mar 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of lipustobart in solid tumor, sponsored by Livzon Pharmaceutical Group Inc. Primary endpoints: Dose Limiting Toxicities, Maximum Tolerated Dose at 17 months and 1 more. Started Aug 2017; status: completed.
02
Drugs
lipustobart
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03286296.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03286296.